Parkinson's disease Nervous System Diseases Parkinson disease
Conditions
Interventions
The study employed a 3 (groups) x 2 (measure times: baseline and 2 months) repeated measures design. Forty participants completed all baseline measurements and then were randomly divided into three gr
Sponsors
Universidad Andres Bello
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Participants of both genders with diagnosis of idiopathic Parkinson's disease (stage I-III Hoehn and Yahr scale) in the “on dopaminergic” state were initially recruited in the study. Inclusion criteria were: 1. Diagnosis of idiopathic Parkinson's disease confirmed by a neurologist 2. Participants with the ability to understand and respond to the instructions given in the study 3. Unaltered dose and type of antiparkinsonian medication 4. Stable disease at the moment of inclusion in this study
Exclusion criteria
Exclusion criteria: 1. Other concomitant neurological disease 2. Current smokers 3. Participants with a history of cardiovascular pathology, lung disease or the presence of respiratory symptoms such as cough, phlegm, wheezing or dyspnoea at the time of assessment 4. Participants with difficulties in maintaining a proper mouth seal or unable to avoid air leakage during pulmonary function testing
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Voluntary and reflex peak cough flow, measured using a pneumotachograph (MLT 1000; ADInstruments, Inc) coupled to a data acquisitions system (PowerLab 8/35, ADInstruments, Inc.), before and after 2 months of inspiratory or expiratory muscle training | — |
Secondary
| Measure | Time frame |
|---|---|
| Current secondary outcome measures as of 23/05/2018: 1. Maximum inspiratory and expiratory pressure, measured using a pressure manometer (Micro RPM, Micro Medical-Care Fusion, Kent, UK) before and after 2 months of inspiratory or expiratory muscle training 2. Slow vital capacity, forced vital capacity and forced expiratory volume in 1s, measured using a digital spirometer (FE141, ADInstruments, Inc.) coupled to a data acquisitions system (PowerLab 8/35, ADInstruments, Inc.) before and after 2 months of inspiratory or expiratory muscle training 3. Subglottic pressure (SGP) and phonation threshold pressure (PTP) were measured during the production of plosives and recorded using a handled battery-operated device (PG-100E, Glottal Enterprises, Canada) connected to a 0.5 inches (inner diameter) silicon tubing and a standard Luer-connector. The opposite end of the silicon tubing was placed between each participant's lips preventing them from biting the tip of the tubing. Participants were instructed to repeat the syllable /pa/ at a rate of 1.5 to 2 seconds until the pressure tachometer inside the device (PG-100E), reached a 3-second plateau. SGP and PTP measurements were performed at three voice intensities: conversational, lowest possible intensity, and highest possible intensity. SGP and PTP were repeated at least 3 times for each voice intensity. The highest value of each voice intensity record was used for further analysis. Voice production intensity during SGP and PTP measurements were recorded using a portable digital recorder (Tascam DR40) sampling rate 44kHz/16-bit, placed at 45º and 20 cm from participants’ lips. Voice recordings were further analyzed using Praat software (Phonetic Sciences, University of Amsterdam. The Netherlands). The mean and maximum sound pressure level (SPL) in decibels were extracted for further analysis. For maximum phonation time (MPT) participants were i | — |
Countries
Chile
Outcome results
None listed